CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

KMT2A rearrangement (relapsed/refractory AML)

Gene: KMT2A · Type: fusion

Indications: Acute myeloid leukemia

SensitivityResistanceCIViC Context

Linked CIViC Profile: KMT2A MUTATION

Evidence Level Distribution

No CIViC evidence found for KMT2A.

No evidence items available.